#USA #Atlanta #fundraising #Airway Therapeutics #Zelpultide Alfa

Airway Therapeutics Secures Major Funding for Zelpultide Alfa

Airway Therapeutics, Inc., a biopharmaceutical firm in late clinical development, has successfully raised $50 million to bolster the advancement of its innovative biological therapy, Zelpultide alfa. This funding is expected to significantly contribute to the ongoing clinical trials focused on preventing bronchopulmonary dysplasia (BPD) in extremely premature infants, a patient group with critical unmet medical needs.

Details of the Funding Round

The recent financing consists of $26 million raised via a SAFE financing agreement and an additional $24 million from the Series E-2 funding round. This round saw a remarkable participation rate, with around 94% of existing investors, including notable contributors such as the Cincinnati Children's Hospital and a coalition of family offices focused on the development of advanced pulmonary therapies.

Dr. Marc Salzberg, Chairman and CEO of Airway Therapeutics, expressed his gratitude for the ongoing confidence from existing investors, highlighting how this funding will enable sustained progress in their late-stage clinical program. He noted the significance of examining Zelpultide alfa's efficacy in preventing BPD, emphasizing the lack of approved preventative therapies for this delicate and vulnerable population.

Clinical Development and Ongoing Trials

The primary objective of the funding is to support the completion of the Phase 2b/3 clinical trial involving Zelpultide alfa. This trial is critical as it aims to evaluate the safety and effectiveness of the therapy in at-risk infants. Additionally, the funds will be allocated towards crucial chemistry, manufacturing, and control (CMC) processes as well as analytical activities that are vital for the program's ongoing development.

The next significant milestone on Airway's roadmap is a planned interim analysis, anticipated to close by the end of the second quarter of 2027. This analysis will mark the completion of the Phase 2b component of the trial, providing important insights into the therapy's performance thus far.

Understanding Zelpultide Alfa

Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) engineered to accurately mirror the native protein's structure and biological function. Its therapeutic action is built upon three primary mechanisms: modulating immune responses to curb excessive inflammation, enhancing the detection and elimination of pathogens, and maintaining surfactant homeostasis to support lung functionality. This versatile biological therapy is designed to cater to patients across all age groups, focusing on BPD prevention in infants while also targeting acute and chronic respiratory, inflammatory, and infectious diseases in adults.

Currently, Zelpultide alfa is navigating through a Phase 2b/3 clinical study for the prevention of BPD, following promising safety and tolerance results from Phase 1b trials.

Airway Therapeutics’ Vision

Airway Therapeutics is committed to redefining the prevention and treatment approaches for respiratory, inflammatory, and infectious diseases through its innovative therapies. Zelpultide alfa stands as a frontrunner in their developmental pipelines, especially concerning the urgent medical needs of premature infants— a demographic lacking effective preventive measures.

As the organization moves forward, it aims not only to meet the immediate needs of specific patient groups but also to explore broader applications across different diseases, thereby improving treatment outcomes for those who need it most. For more information about Airway Therapeutics and its innovative research, visit their website at airwaytherapeutics.com.